26th week of 2012 patent applcation highlights part 56 |
Patent application number | Title | Published |
20120165189 | COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASES - The present invention provides a composition for controlling plant diseases comprising, as active ingredients, a compound represented by formula (1) and ethaboxam. | 2012-06-28 |
20120165190 | Treating Harvested Crops - A method can include providing an emulsion that includes a compound that repels birds and applying the emulsion to harvested grain. Harvested, treated grain can include an emulsion that includes a compound that repels birds. A method can include applying an emulsion that includes a compound that repels birds to an animal boarding facility. Other exemplary compounds, compositions, methods and devices are also disclosed. | 2012-06-28 |
20120165191 | SYNERGISTIC COMBINATION OF A GLYPHOSATE COMPOUND AND IPBC - A synergistic antimicrobial composition containing a glyphosate compound and 3-iodo-2-propynyl-butylcarbamate is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition. Also provided is a method of making zinc glyphosate. | 2012-06-28 |
20120165192 | SYNERGISTIC COMBINATION OF A GLYPHOSATE COMPOUND AND ONE OF DCOIT OR OIT OR BBIT - A synergistic antimicrobial composition containing a glyphosate compound and one of 4,5-dichloro-2-n-octyl-4-isothiazolin-3-one or 2-n-octly-4-isothiazolin-3-one or N-Butyl-1,2-benzisothiazolin-3-one is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition. | 2012-06-28 |
20120165193 | SYNERGISTIC COMBINATION OF A GLYPHOSATE COMPOUND AND TBZ - A synergistic antimicrobial composition containing a glyphosate compound and thiabendazole is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition. | 2012-06-28 |
20120165194 | SYNERGISTIC COMBINATION OF A GLYPHOSATE COMPOUND AND ZPT - A synergistic antimicrobial composition containing a glyphosate compound and zinc pyrithione is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition. | 2012-06-28 |
20120165195 | Agricultural Adjuvant Compositions, Pesticide Compositions, and Methods for Using Such Compositions - An adjuvant composition for use with a pesticide contains at least one surfactant compound selected from each of at least two of the following groups:(i) phosphate ester surfactants, (ii) alkylpolyglucoside surfactants, (iii) the group consisting of imidazoline-based amphoteric surfactants, sultaine surfactants, and aminopropionate surfactants, and (iv) the group consisting of sulfonate surfactants, sulfosuccinate surfactants, alkyl ether carboxylate surfactants, alkoxylated fatty acid surfactants, and alkoxylated alcohol surfactants. A pesticide composition contains the adjuvant composition and a pesticide is useful for treating plants. | 2012-06-28 |
20120165196 | HYDRATE OF SULFONYLUREA COMPOUND, PROCESS FOR PRODUCING THE SAME AND SUSPENSION FORMULATION CONTAINING THE SAME - The present invention relates to a hydrate of sulfonylurea compound represented by formula (I): | 2012-06-28 |
20120165197 | CRYSTAL MODIFICATION OF MESOTRIONE - The invention relates to a crystalline polymorph Form 3 of 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohex-anedione. A process for its preparation, use thereof for the control of weeds, and an herbicidal composition comprising thereof are also disclosed. | 2012-06-28 |
20120165198 | SUPERCONDUCTING ELECTRIC MOTOR - A superconducting electric motor includes: a rotor that is rotatably arranged; and a stator that is arranged in a radial direction of the rotor so as to face the rotor. The stator has a plurality of superconducting coils that are wound at a radial end portion of a stator core and that are formed of a superconducting wire material. The superconducting electric motor includes a refrigerator that has at least one narrow tube that flows low-temperature refrigerant inside. The at least one narrow tube is in thermal contact with the stator core and at least one of the coils. | 2012-06-28 |
20120165199 | TAPE BASE FOR SUPERCONDUCTING WIRE, AND SUPERCONDUCTING WIRE - A tape-shaped base for a superconducting wire, which simplifies the intermediate layer and thus enables production of a superconducting wire at lower cost, and which is capable of improving the characteristics (such as electrical conduction and handling properties) of a superconducting wire; and a superconducting wire. Specifically disclosed is a tape-shaped base for a superconducting wire, which is obtained by forming an intermediate layer on a metal substrate. In the tape-shaped base for a superconducting wire a biaxially oriented layer of the intermediate layer is configured of a niobium monoxide (NbO) layer that is formed by depositing vapor deposition particles from a vapor deposition source on a film formation surface. | 2012-06-28 |
20120165200 | METHODS FOR MAKING LOW RESISTIVITY JOINTS - Method for joining wires using low resistivity joints is provided. More specifically, methods of joining one or more wires having superconductive filaments, such as magnesium diboride filaments, are provided. The wires are joined by a low resistivity joint to form wires of a desired length for applications, such in medical imaging applications. | 2012-06-28 |
20120165201 | SIMULTANEOUS, INTEGRATED SELECTION AND EVOLUTION OF ANTIBODY/PROTEIN PERFORMANCE AND EXPRESSION IN PRODUCTION HOSTS - The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization. | 2012-06-28 |
20120165202 | METHODS AND COMPOSITIONS FOR EVALUATING GENETIC MARKERS - Aspects of the invention relates to methods and compositions that are useful to reduce bias and increase the reproducibility of multiplex analysis of genetic loci. In some configurations, predetermined preparative steps and/or nucleic acid sequence analysis techniques are used in multiplex analyses for a plurality of genetic loci in a plurality of samples. | 2012-06-28 |
20120165203 | SIMULTANEOUS DETERMINATION OF ANEUPLOIDY AND FETAL FRACTION - The invention provides compositions and methods for simultaneously determining the presence or absence of fetal aneuploidy and the relative amount of fetal nucleic acids in a sample obtained form a pregnant female. The method encompasses the use of sequencing technologies and exploits the occurrence of polymorphisms to provide a streamlined noninvasive process applicable to the practice of prenatal diagnostics. | 2012-06-28 |
20120165204 | Genetically Encoded Photomanipulation of Protein and Peptide Activity - The present invention relates to fusion proteins comprising protein light switches and methods of photomanipulating the activity of the proteins. The invention further relates to polynucleotides and vectors encoding the fusion proteins, cells comprising the fusion proteins, and methods of using the fusion proteins to study protein function and analyze subcellular activity, as well as diagnostic and therapeutic methods. | 2012-06-28 |
20120165205 | METHOD FOR SEQUENCING A POLYNUCLEOTIDE TEMPLATE - A method of determining the sequence of a target nucleic acid is provided. The method can include the steps of (a) performing a defined number of incremental extension cycles to produce a population of nucleic acid fragments having different portions of the target nucleic acid wherein the individual nucleic acid fragments in the population have a defined length that is correlated with the number of incremental extension cycles; (b) determining the sequence of the first end of individual nucleic acid fragments in the population, thereby providing first end sequences; (c) determining the sequence of the second end of individual nucleic acid fragments in the population, thereby providing second end sequences; and (d) determining the sequence of the target nucleic acid based on the first end sequences, the second end sequences and the defined length. | 2012-06-28 |
20120165206 | Method and Assay for Glycosylation Pattern Detection Related to Cell State - A method and assay for characterizing populations of cells according to their glycosylation pattern, particularly for distinguishing between cell populations. In preferred embodiments the present invention is able to determine the state of a stem cell (ie differentiated or undifferentiated) and/or the state of a cancer cell, for example with regard to malignancy. Preferably the present invention is also able to determine whether a patient is likely to respond to a drug according to the glycosylation pattern of a sample of cancer cells taken from the patient (or alternatively examined while in the patient, as described in greater detail below). Also optionally, it may be used to analyze a cell population before and after treatment with a drug for example. | 2012-06-28 |
20120165207 | Methods for Monitoring Allograft Rejection - Methods are provided for monitoring an allograft recipient for a rejection response, e.g., to predict, to diagnose, and/or to characterize a rejection response. In practicing the subject methods, the level of at least one protein in a sample from the allograft recipient, e.g., serum, urine, blood, CSF, tears or saliva, is evaluated, to monitor the subject. Also provided are compositions, systems, and kits that find use in practicing the subject methods. | 2012-06-28 |
20120165208 | METHOD FOR PREDICTING THE RESPONSIVENESS OF A PATIENT TO A TREATMENT WITH AN ANTI-CD20 ANTIBODY AND A METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS - The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of miR-125b expression in a biological sample obtained from said patient. The present invention also relates to a method for diagnosing rheumatoid arthritis in a patient, said method comprising measuring the level of miR-125b expression in a biological sample obtained from said patient. | 2012-06-28 |
20120165209 | METHODS AND COMPOSITIONS FOR DIRECTED MICROWAVE CHEMISTRY - The present invention concerns a novel means by which chemical preparations can be made. Reactions can be accelerated on special cartridges using microwave energy. The chips contain materials that efficiently absorb microwave energy causing chemical reaction rate increases. The invention is important in many chemical transformations including those used in protein chemistry, in nucleic acid chemistry, in analytical chemistry, and in the polymerase chain reaction. | 2012-06-28 |
20120165210 | RAPID GENOTYPING ANALYSIS AND THE METHOD THEREOF - The present invention describes methods of performing rapid nucleic acid detection using a flow through process. The methods comprise single-step signal amplification and/or a one-step hybridization protocol. Using the flow through hybridization process, the present invention provides a more efficient, faster and less expensive genotyping method. This invention further provides a Single Nucleotide Polymorphism (SNP)-based DNA fingerprinting method for rapid and accurate genotyping, identification as well as DNA analyses of genetic materials from human beings and other different organisms. In addition this invention also discloses devices for rapid and sensitive analysis of target analysts. | 2012-06-28 |
20120165211 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques - The present invention refers to human antibodies derived from human antibody libraries prepared from atherosclerotic plaques. It further refers to human antibodies able to immunologically recognize both human transgelin or fragments thereof and a protein with at least 50% similarity to OmpK36 (Outer membrane protein, | 2012-06-28 |
20120165212 | Method for the detection of gene transcripts in blood and uses thereof - The present invention relates generally to the identification of biomarkers of conditions including disease and non disease conditions as well as identifying compositions of biomarkers. The invention further provides a method of diagnosing disease, monitoring disease progression, and differentially diagnosing disease. The invention further provides for kits useful in diagnosing, monitoring disease progression and differentially diagnosing disease. | 2012-06-28 |
20120165213 | Methods, Reagents and Kits for Flow Cytometric Immunophenotyping - The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions. | 2012-06-28 |
20120165214 | METHODS AND COMPOSITIONS FOR ASSESSMENT OF PULMONARY FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer, and the suitability of a subject for an intervention in respect of lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 2012-06-28 |
20120165215 | METHODS AND SYSTEMS FOR PHYLOGENETIC ANALYSIS - The present invention discloses methods and systems for designing and using organism-specific and/or operational taxon unit (OTU)-specific probes. The methods and systems allow for detecting, identifying and quantitating a plurality of biomolecules or microrganisms in a sample based on the hybridization or binding of target molecules in the sample with the probes. Some embodiments provide methods of selecting an oligonucleotide probe specific for a node on a clustering tree. Other embodiments provide methods of selecting organism-specific or OTU-specific oligonucleotide probes for use in accurately detecting a plurality of organisms in a sample with high confidence. Some embodiments provide methods and systems to detect the presence of a rare OTU in a sample. | 2012-06-28 |
20120165216 | METHOD FOR IDENTIFYING SENESCENT MESENCHYMAL STEM CELLS - The invention refers to a method for identifying senescent mesenchymal stem cells growing in in vitro culture, comprising: measuring the length of chromosome telomeres, determining the level of ploidy in the cell, detecting the presence of multipolar mitosis and determining the level of expression of the genes SCIN, AKAP9, EDN-1, CXCL1, CXCL12 and/or CD70. This method can be used for performing genetic stability studies in mesenchymal stem cell cultures, enabling identification and selection of the most stable and appropriate cells for use in cell therapy. | 2012-06-28 |
20120165217 | Cancer Biomarkers and Uses Thereof - The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 24, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value. | 2012-06-28 |
20120165218 | METHOD AND ASSAY FOR DETERMINING FAS EXPRESSION - Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer. | 2012-06-28 |
20120165219 | DEVICES AND METHODS FOR MICROARRAY SELECTION - The present invention relates to a device for the specific selection of target molecules, comprising: (a) at least one reaction zone comprising a microarray, wherein the microarray comprises a substrate, on which one or more species of capture molecules are immobilized, comprising one or more temperature control and/or regulating units for controlling and/or regulating the temperature within the zone; (b) at least one non-reaction zone comprising one or more temperature control and/or regulating units for controlling and/or regulating the temperature within the zone, which is in fluid connection with the reaction zone; and (c) at least one transportation means capable of generating and/or regulating a fluid flow between said reaction zone (a) and said non-reaction zone comprising one or more temperature control and/or regulating units (b). The present invention further relates to a device for the specific selection of target molecules wherein the immobilized capture molecules are organized in the microarray in the form of spots, elongated spots and/or lines. In a further aspect the present invention relates to a method of specifically selecting target molecules, comprising the introducing a medium to such a device, performing interaction reactions in a reaction zone, transporting not interacted or not bound target molecules to a zone allowing reactivation of the target molecules and performing additional interaction reactions with the reactivated target molecules at the reaction zone, as well as the use of such a device for specifically selecting target molecules, e.g. for target enrichment also referred to as microarray based genome selection (MGS) in the literature. | 2012-06-28 |
20120165220 | Uses of CD116 Expression Level - The present invention provides methods for using granulocyte macrophage colony-stimulating factor receptor (CD116) expression level for various clinical applications including, but not limited to, diagnosing inflammatory bowel disease in a subject. | 2012-06-28 |
20120165221 | DIAGNOSIS OF CANCERS THROUGH GLYCOME ANALYSIS - Markers and methods of diagnosis and monitoring of cancer through global glycome analysis. | 2012-06-28 |
20120165222 | METHODS AND SYSTEMS FOR ANALYSING HYBRIDISATION - A method is described for the analysis of hybridisation between a target in solution and a probe bound at a surface. The method comprises receiving detection intensity results for hybridisation of the target with a plurality of different probes, the probes being selected so that a range of hybridisation detection intensity results for the hybridisation between the target and the probe is covered. The method further comprises analysing the detection intensity results as function of the hybridisation free energy. According to embodiments of the present invention, the receiving and/or analysing takes into consideration a thermodynamic non-equilibrium state for the target-probe bounding state. | 2012-06-28 |
20120165223 | Human Intestinal Normal Bacterial Flora DNA Chip and Method for Estimating Harmness to Human Body Due to Change of Human Intestinal Normal Bacterial Flora Using DNA Chip - The present invention relates to a DNA chip showing specific responses to a human intestinal normal bacterial flora and a method for estimating harmness to the human bodies due to the change of the human intestinal normal bacterial flora using the DNA chip. | 2012-06-28 |
20120165224 | CELL CHIP - Disclosed herein is a cell chip including: an upper substrate having a plurality of biometrics spaced therefrom by fillers, the biometrics fixing a biomaterial thereinto; a first hydrophobic coating layer formed on the upper substrate; and a lower substrate combined with the upper substrate and having a plurality of wells formed therein, the well storing fluid provided to the biometrics therein. The cell chip includes two substrates functionally separated from each other to implement a three dimensional cell chip, solves a cross contamination problem, and provides a similar environment to a bio environment, thereby making it possible to increase the accuracy of a test. | 2012-06-28 |
20120165225 | FUNCTIONAL BIOMOLECULES AND METHODS - The present invention is generally directed to novel functionalized biomolecules and methods for generating such biomolecules. Biomolecules may generally include nucleic acids, peptides, multicomponent molecular complexes and/or any other molecular products that may be produced by living organisms. The present invention is further directed to cells and/or organisms manipulated to produce such functionalized biomolecules. The cells contemplated by the present invention include both prokaryotic as well as eukaryotic cells. The functionalized biomolecules are produced via materials introduced into the cell using standard molecular biology techniques or are incorporated within the genomic nucleic acid of a cell by standard recombination techniques. Further contemplated is the use of such cells for sequestration of target molecules within the cells. | 2012-06-28 |
20120165226 | PHAGE DISPLAY - The transformation yield of electroporation is increased by using higher DNA concentrations and DNA affinity purification. Fusion proteins of a viral coat protein variant and a heterologous polypeptide are useful in phage display systems. | 2012-06-28 |
20120165227 | COMPOUNDS AND METHODS FOR DETECTION AND QUANTIFICATION OF CARBOXYLIC ACIDS - The present disclosure includes compounds of Formula I: wherein R | 2012-06-28 |
20120165228 | EVOLVING NEW MOLECULAR FUNCTION - Nature evolves biological molecules such as proteins through iterated rounds of diversification, selection, and amplification. The present invention provides methods, compositions, and systems for synthesizing, selecting, amplifying, and evolving non-natural molecules based on nucleic acid templates. The sequence of a nucleic acid template is used to direct the synthesis of non-natural molecules such as unnatural polymers and small molecules. Using this method combinatorial libraries of these molecules can be prepared and screened. Upon selection of a molecule, its encoding nucleic acid template may be amplified and/or evolved to yield the same molecule or related molecules for re-screening. The inventive methods and compositions of the present invention allow for the amplification and evolution of non-natural molecules in a manner analogous to the amplification of natural biopolymer such as polynucleotides and protein. | 2012-06-28 |
20120165229 | OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, SCREENING, ISOLATION AND SEQUENCING OF MRSA, MSSA, STAPHYLOCOCCUS MARKERS, AND THE ANTIBIOTIC RESISTANCE GENE MEC A - Described herein are primers and probes useful for the detection, screening, isolation and sequencing of MRSA, MSSA, Staphylococci markers, and the antibiotic resistance gene mecA. | 2012-06-28 |
20120165230 | BIOLOGICALLY PRODUCED CYCLIC AFFINITY TAGS - Described are novel ways of introducing an affinity tag into a protein of interest. Provided is an enzymatic method for providing a proteinaceous substance comprising a polypeptide of interest and a cyclic affinity tag, comprising: (a) providing at least one precursor proteinaceous substance, the precursor comprising the protein of interest and at least one motif of the general formula X1-Tag-X2, wherein X1 and X2 represent amino acids whose side chains can be linked enzymatically by a covalent bond; Tag is a short amino acid sequence capable of binding to a binding partner of the tag when cyclized; (b) contacting the precursor with at least one enzyme capable of forming a covalent bond between X1 and X2, thereby introducing an intramolecular ring structure comprising the Tag sequence; and (c) isolating the resulting cyclized proteinaceous substance. Also provided are proteinaceous substances obtainable thereby and the use thereof, for instance, for preparing a peptide library. | 2012-06-28 |
20120165231 | Drilling Fluids Having Reduced Sag Potential and Related Methods - Invert emulsion drilling fluids that have extended emulsion stability and reduced sag potential are described herein. The drilling fluids comprise an invert emulsion, a weighting agent, and a plurality of colloidal particles. The invert emulsion comprises an oleaginous fluid continuous phase, an aqueous fluid internal phase, and a surfactant. At least a portion of the plurality of colloidal particles interact with the surfactant to form an associative supporting structure that inhibits sag of the weighting agent. In some embodiments, the weighting agent comprises barite particles, particularly barite particles that are less than about 45 μm in size. Methods for placing the invert emulsion drilling fluids in a subterranean formation via a wellbore are also disclosed. | 2012-06-28 |
20120165232 | Methods of Controlling the Degradation Rate of Hydrolytically Degradable Materials - Methods of affecting the rate at which a hydrolytically degradable material degrades comprising: providing a hydrolytically degradable material, the degradable material having an intrinsic degradation rate; providing a modifier, the modifier being capable of affecting the intrinsic degradation rate of the hydrolytically degradable material; placing the hydrolytically degradable material and the modifier into a subterranean formation; and allowing the modifier to affect the intrinsic degradation rate of the hydrolytically degradable material so that the hydrolytically degradable material degrades at a second degradation rate. | 2012-06-28 |
20120165233 | GRAVEL PACK FLUID COMPOSITION AND EMULSION THEREFOR - A gravel pack composition comprising i) a water-in-oil emulsion comprising: a) an organic continuous phase comprising 0.1 to 5 vol % of the emulsion of non-ionic or cationic surfactant and 0.25 to 3 vol % of the emulsion of sorbitan ester; b) a dispersed aqueous phase comprising 0.05 to 3 vol % of the emulsion of a partial ester of a polyol with at least one C6 to C22 fatty acid and at least one of an acid, acid precursor, and a chelating agent; and c) a density control agent; and ii) gravel. The fluid can display a delayed break of up to about 72 hours to enable clean-up of mud cake. | 2012-06-28 |
20120165234 | Tartaric Acid and Amine Derivatives in Crankcase Oils and Fuel Compositions adn Preparation Thereof - Formulations using tartaric compounds of the present invention in a low sulfur, low ash and low phosphorous lubricant lower wear, and friction and improves fuel economy. | 2012-06-28 |
20120165235 | GLYCEROL-CONTAINING FUNCTIONAL FLUID - A functional fluid comprising a major amount of an oil of lubricating viscosity, and greater than about 0.05 wt-% glycerol. A method of preparing a functional fluid comprising adding glycerol to a functional fluid, wherein the glycerol is not glycerol monooleate. A method of preparing an additive concentrate comprising adding glycerol to a diluent oil wherein the concentrate contains from about 1% to about 99% by weight of said diluent. A method of reducing friction comprising contacting a metal surface with a functional fluid comprising a major amount of an oil of lubricating viscosity and greater than about 0.05 wt-% glycerol. | 2012-06-28 |
20120165236 | CLEANSING AGENT - To prevent a photocatalyst-containing cleansing agent from deteriorating and maintain the sterilizing cleansing and deodorant effects, provided is a cleansing agent characterized by containing a photocatalyst, fine powder of charcoal that is activated carbon, and cyclodextrin. It is desirable that the charcoal is charcoal or activated carbon. By adding a fine powder of charcoal in addition to the photocatalyst, it is possible to inhibit the oxidation reaction of the photocatalyst during storage by the light blocking effect, and to prevent the effects of the cleansing agent from degrading. Further, it is possible to efficiently exert cooperative action of adsorbing excess sebum, pore-clogging dirt, cuticle, waste products, smells, etc. due to the porous structure of charcoal, and further, decomposing the adsorbed materials by the photocatalyst. | 2012-06-28 |
20120165237 | DETERGENT COMPOSITION CONTAINING AN AMINOCARBOXYLATE AND A MALEIC COPOLYMER - Detergent compositions including at least one aminocarboxylate, at least one maleic/methylvinyl ether copolymer, an alkaline agent and optional additives. Embodiments of the present invention include reduced concentrations of aminocarboxylate compared to conventional compositions, while preventing scale accumulation and providing stain removal capability. | 2012-06-28 |
20120165238 | Droplet-Based Surface Modification and Washing - The present invention relates to droplet-based surface modification and washing. According to one embodiment, a method of modifying a surface on a droplet microactuator is provided, wherein the method includes executing one or more droplet operations to bring a droplet comprising a surface-modifying agent into contact with the surface. According to another embodiment, a droplet microactuator is provided and includes a sample or reagent immobilized on a surface thereof and arranged such that a droplet on the droplet microactuator may contact the surface. According to yet another embodiment, a method of removing a substance from a surface to which the substance is bound is provided, the method including conducting one or more droplet operations to contact a droplet with the surface, the droplet comprising a solution for eluting the substance from the surface | 2012-06-28 |
20120165239 | SOLID FRAGRANCE-EMITTING COMPOSITION - Herein a solid, scent-imparting composition is disclosed that comprises a water-soluble support, a water-soluble polymer, a malodor-absorbing compound, and a perfume. In a preferred embodiment of the present invention, the water-soluble support is provided as a particulate that is coated with an envelope consisting of the water-soluble polymer, the malodor-absorbing compound, and the perfume. A detergent compound may be included that is at least partly in and/or on the envelope. Washing or cleaning agents comprising the scent-imparting compositions are also described. | 2012-06-28 |
20120165240 | READY TO USE THICKENED DEGREASER AND ASSOCIATED METHODS - Cleaner compositions, methods of making cleaners, and methods of use are disclosed. Disclosed is a method of formulating a ready-to-use degreaser composition that has extended to infinite cling time. The method of making the cleaner results in thickened compositions that are capable of removing from vertical and inverted surfaces fresh, greasy and baked-on soils encountered in the food industry. The compositions include one or more alkalinity sources, one or more chelants, one or more surfactants, one or more thickening agents, one or more solvents, one or more buffers, and as a remainder, water. Compositions prepared according to the method of the invention are substantially free of phosphorous and have a low caustic content making them user and having a lower pH than commercially available cleaners. Yet the cleaners prepared according to the method of the invention are surprisingly effective at removing tenacious baked-on soils encountered in the food service industry. | 2012-06-28 |
20120165241 | Subtilase Variants - The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved stability and/or improved wash performance in any detergent in comparison to their wild type parent enzymes. The enzymes are well-suited for use in any detergent and for some in especially liquid or solid shaped detergent compositions. | 2012-06-28 |
20120165242 | POLYMERS FOR HIGH-SURFACTANT FORMULATIONS - A detergent composition having at least two components. The first component is from 14 to 50 wt % surfactants. The second component is from 0.05 to 4 wt % of a polymer which has polymerized residues of 40 to 65 wt % C | 2012-06-28 |
20120165243 | USE OF DIETARY FIBRES AGAINST MUSCLE WASTING - A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units. | 2012-06-28 |
20120165244 | METHODS FOR BINDING LEWIS Y ANTIGEN - The present invention relates to a method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues. | 2012-06-28 |
20120165245 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING - The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. | 2012-06-28 |
20120165246 | Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor - The present invention provides a method of specifically detecting the presence of one or more Mycobacteria of the | 2012-06-28 |
20120165247 | USE OF A COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF PLANTS AND RELATIVE COMPOSITION - A method of using a beef extract or a protein hydrolisate or a mixture of beef extract and protein hydrolisate, as active substance, for treatment and/or prophylaxis of plants against the action of pathogens is described. A composition including a beef extract or a protein hydrolisate or a mixture of beef extract and protein hydrolisate, as active substance, for treatment and/or prophylaxis of plants against the action of pathogens is also described. | 2012-06-28 |
20120165248 | Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases - Glutathione derivatives (GSH) of formula I are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus. | 2012-06-28 |
20120165249 | Stabilized Therapeutic Small Helical Antiviral Peptides - Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus. | 2012-06-28 |
20120165250 | Active Cores of Peptide Triazole HIV-1 Entry Inhibitors - The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. Further provided are an antibody to the peptide triazole conjugate, and a method of identifying an HIV-I entry inhibitor candidate. | 2012-06-28 |
20120165251 | Diabetes therapy - The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use. | 2012-06-28 |
20120165252 | Method of Regulating Glucose Metabolism, and Reagents Related Thereto - The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. | 2012-06-28 |
20120165253 | PHARMACEUTICAL COMPOSITION FOR INHIBITING PERITONEAL DISSEMINATION - A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and an acceptable receptor thereof. | 2012-06-28 |
20120165254 | SULPHATED HYALURONIC ACID FOR TREATING DEGENERATIVE OSTEOARTHRITIS - This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis. | 2012-06-28 |
20120165255 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD FOR PERIODONTAL DISEASES AND PULPAL DISEASES - The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue.
| 2012-06-28 |
20120165256 | USE OF ERYTHROPOIETIN AND SUBSTANCES INCREASING AND/OR PROLONGING THE ACTIVATION AND/OR STIMULATION OF ERYTHROPOIETIN RECEPTORS FOR TREATING AND/OR PREVENTING SCHIZOPHRENIA AND RELATED PSYCHOSES - Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being. | 2012-06-28 |
20120165257 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 2012-06-28 |
20120165258 | Compositions and Methods for Treatment of Thrombosis and for Prolonging Survival of Stored Platelets - Provided herein are methods and compositions, including pharmaceutical compositions, for treating thrombosis, vascular inflammation, and thrombocytopenia. The methods and compositions of the present invention are also useful for extending the useful storage shelf life of platelets. | 2012-06-28 |
20120165259 | AGENT FOR AMELIORATING BLOOD-BRAIN BARRIER DISORDERS - The invention provides a method of ameliorating a blood-brain barrier disorder, as well as a method of treating a disease accompanied by a blood-brain barrier disorder and a method of treating a cerebral ischemic disease, by administering a prothymosin α, or a protein or polypeptide possessing the same function as the prothymosin α. The invention also provides polypeptides useful in the context of the aforesaid methods. | 2012-06-28 |
20120165260 | CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATE - Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride. | 2012-06-28 |
20120165261 | Alpha-1-antitrypsin compositions - A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described. | 2012-06-28 |
20120165262 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS INVOLVING EPITHELIAL CELL APOPTOSIS - The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient. | 2012-06-28 |
20120165263 | BONE REGENERATION AGENT COMPRISING GELATIN - It is an object of the present invention to provide a bone regeneration agent and a bone supplementation formulation, in which a supplementation material itself is capable of promoting bone regeneration. The present invention provides a bone regeneration agent which comprises a gelatin having an amino acid sequence derived from a partial amino acid of collagen. | 2012-06-28 |
20120165264 | Degradation-Stabilised, Biocompatible Collagen Matrices - The present invention relates to degradation-stabilised, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use of the collagen matrices according to the invention as a cosmetic or pharmaceutical agent, in particular for topical use, and as a wound treatment agent, as an implant or as a haemostatic agent in humans or animals, and as a scaffold for cell population in the biotechnology, basic research and tissue engineering field. | 2012-06-28 |
20120165265 | Calcium Signaling Modulators Involving STIM and ORAI Proteins - The present invention provides compositions and methods for investigating the structural basis of the activation process of CRAC channels, which are essential for T-lymphocyte activation and adaptive immunity. The invention also provides compositions and methods to design, identify and evaluate agents that modulate calcium signaling by regulating the interaction between STIM and Orai proteins. The invention also provides therapeutic agents for cases of immunological disorders, compromised immune function, organ transplantation, or thrombosis. | 2012-06-28 |
20120165266 | METHOD FOR PREPARING GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROETIN FROM PANAX GINSENG, AND GINTONIN, WHICH IS A NOVEL GLYCOLIPOPROTEIN, PREPARED BY THE METHOD - Disclosed are the novel glycolipoprotein gintonin isolated and identified from ginseng, a method for preparing the same, and uses thereof. Gintonin causes a transient increase in intracellular free Ca | 2012-06-28 |
20120165267 | Apo-2 LIGAND/TRAIL VARIANTS AND USES THEREOF - The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided. | 2012-06-28 |
20120165268 | P53 FUSION PROTEINS AND METHODS OF MAKING AND USING THEREOF - Biologically active tetrameric p53 proteins and p53 fusion proteins are provided. These proteins may be generated and refolded into tetrameric form using denatured proteins produced from | 2012-06-28 |
20120165269 | Tumor Cell-Killing Peptides - The present invention provides a tumor cell-killing peptide and a pharmaceutical composition for treating a cancer. The tumor cell-killing peptide of the present invention selectively homes into tumor cells so that it can induce the death of tumor cells effectively while minimizing the harming of normal cell. | 2012-06-28 |
20120165270 | INHIBITION OF HAIR FOLLICLE GROWTH BY THE WNT INHIBITOR DKK1 - The invention provides methods of inhibiting hair growth in a post-natal subject by contacting a matured hair follicle cell with a DKK polypeptide. The inhibitory mechanism induced by a DKK polypeptide results in a reversible, transient inhibition of hair growth. | 2012-06-28 |
20120165271 | METHODS OF TREATING RETINITIS PIGMENTOSA - The present invention relates to methods of treating retinitis pigmentosa using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa. | 2012-06-28 |
20120165272 | Tear Substitutes - The invention features ophthalmic formulations of mucin polypeptides to treat or prevent dry eye. | 2012-06-28 |
20120165273 | EYE DROPS - An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH | 2012-06-28 |
20120165274 | THREE-DIMENSIONAL STRUCTURES OF TALL-1 AND ITS COGNATE RECEPTORS AND MODIFIED PROTEINS AND METHODS RELATED THERETO - Disclosed are TALL-1 and TALL-1 receptor protein homologues (agonists and antagonists) designed based on the three-dimensional structure of sTALL-1, eBCMA and eBAFF-R; agonist homologues of APRIL; methods of using wild-type APRIL to inhibit the activity of TALL-1; compositions comprising such homologues, nucleic acid molecules encoding such homologues, and therapeutic methods of using such compounds and compositions. Also disclosed are crystalline complexes of sTALL-1 and sTALL-1 in complex with either BCMA or BAFF-R; models of three-dimensional structures of such crystalline complexes and related structures, methods of drug design using any portion of such structures; methods of design and/or identification of regulatory peptides derived from the such structures; compounds identified by drug design using such structures; and the use of such compounds in therapeutic compositions and methods. | 2012-06-28 |
20120165275 | Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules - Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis. | 2012-06-28 |
20120165276 | QUATERNARY ALKYL AMMONIUM BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism. | 2012-06-28 |
20120165277 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS - Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula: | 2012-06-28 |
20120165278 | Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same - The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof. | 2012-06-28 |
20120165279 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C - A pharmaceutical composition for preventing or treating hepatitis C is provided, including oleanolic acid derivatives as an active ingredient and a pharmaceutically acceptable carrier. A method for preventing or treating hepatitis C in a subject in need thereof is also provided by administering the subject the pharmaceutical composition given above. | 2012-06-28 |
20120165280 | METHOD FOR IMPROVING BLOOD FLOW USING STILBENOID DERIVATIVES - The present invention generally provides methods for using stilbenoid derivatives to improve blood flow and microcirculation. | 2012-06-28 |
20120165281 | STILBENOID DERIVATIVES AND THEIR USES - The present invention generally provides stilbenoid derivatives and methods for using stilbenoid derivatives to modulate the activity of cannabinoid receptors or scavenge reactive nitrogen species. | 2012-06-28 |
20120165282 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II): | 2012-06-28 |
20120165283 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS - This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them. | 2012-06-28 |
20120165284 | PHARMACEUTICAL COMPOSITION COMPRISING A3 ADENOSINE RECEPTOR AGONIST (IB-MECA/CF-101) FOR TREATMENT OF PSORIASIS - The present invention is based on the clinical finding that twice daily administrations of 2 mg of 1-[N | 2012-06-28 |
20120165285 | COMBINED PREPARATION FOR USE AS A MEDICAMENT - A combined preparation comprising an A | 2012-06-28 |
20120165286 | CYCLIC NUCLEOTIDE ANALOGS - Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs. | 2012-06-28 |
20120165287 | COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT - The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent. | 2012-06-28 |
20120165288 | AZAPEPTIDE DERIVATIVES - This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir. | 2012-06-28 |